Management of Chronic Spontaneous Urticaria Made Practical: What Every Clinician Should Know
Authors:
Open Access
- 21 July 2025
- journal article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
Abstract
No abstract availableKeywords
This publication has 146 references indexed in Scilit:
- Cost and Cost-Effectiveness of the Management Strategies of Chronic UrticariaJAMA Dermatology, 2024
- Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for DiscontinuationJAMA Dermatology, 2024
- A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown‐CSU studyClinical and Translational Allergy, 2024
- CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticariaClinical and Translational Allergy, 2024
- Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t KnowAmerican Journal of Clinical Dermatology, 2023
- Evaluation of Pharmacologic Treatments for H1 Antihistamine–Refractory Chronic Spontaneous UrticariaJAMA Dermatology, 2021
- Association Between Fexofenadine Use During Pregnancy and Fetal OutcomesJAMA Pediatrics, 2020
- Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World EvidenceClinical Reviews in Allergy & Immunology, 2020
- Antipruritische Wirksamkeit einer hoch dosierten AntihistaminikatherapieDie Dermatologie, 2009
- Cyclosporin a inhibits the release of histamine and peptide leukotriene C4 from human lung mast cellsLa Ricerca in Clinica e in Laboratorio, 1988